Navigation Links
NexBio to Present at 2009 Biotech Showcase
Date:1/13/2009

SAN DIEGO, Jan. 13 /PRNewswire/ -- NexBio, a privately held development-stage biopharmaceutical company located in San Diego, announced today that David Wurtman, MD, MBA, Vice President of Corporate Development, will present a corporate overview at the upcoming 2009 Biotech Showcase in San Francisco, CA, on January 14, 2009 at 2:15pm. NexBio's corporate mission is to save lives and to improve the quality of life by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening diseases.

NexBio's pipeline consists of two novel biopharmaceuticals invented internally, DAS181 (Fludase(R)), in clinical development, and Viradin(TM), at lead optimization stage, as well as TOSAP(TM), an important new microparticle formulation technology. Corporate funding to date has been entirely non-dilutive, consisting of five grants totaling $13M, together with a BAA Contract for $49.8M to support Fludase(R) development, all from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

Fludase(R) is a broad-spectrum drug candidate for the prophylaxis and treatment of respiratory infections by all variations of influenza virus, including the types of virus that may cause a potential influenza pandemic. In addition, Fludase(R) has the potential for prophylaxis and treatment of seasonal influenza-like illness due to multiple respiratory viruses, including parainfluenza virus, which may cause a serious respiratory illness similar to influenza and for which there is no approved vaccine or therapeutic. Fludase(R) is a recombinant fusion protein that inactivates viral receptors on the cells of the human respiratory tract, thereby preventing influenza and parainfluenza viruses both from infecting the human body and from amplifying in already-infected individuals. Fludase(R) effectively inhibits numerous strains of influenza and parainfluenza virus nonclinical models. Unlike current antiviral compounds and vaccines, Fludase(R) targets human host receptors, not virus components, and thus carries a reduced risk of drug resistance compared with currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance.

Viradin(TM) is a highly-stable protein, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fever caused by viruses such as Ebola and Marburg, as well as the treatment of sepsis and septic shock. TOSAP(TM) is a novel, elegant, inexpensive & easily scalable microparticle formulation technology invented and developed by NexBio, used to formulate Fludase for inhalation as well as the compounds of partners, under license. NexBio has recently begun a collaboration with a Pharma company to formulate one of their proprietary antibodies. TOSAP has been shown to successfully formulate multiple classes of molecule, such as protein (including peptides and antibodies), small molecule, oligonucleotides (including siRNA) and virus.

For more information about NexBio, Inc., please visit http://www.nexbio.com

    Contact:

    David Wurtman, M.D., M.B.A
    VP, Corporate Development
    10665 Sorrento Valley Road
    San Diego, CA  92121
    Phone: (858) 452-2631
    dwurtman@nexbio.com

Note: FDA has yet to approve the name Fludase.

DISCLOSURE NOTICE:

This release contains forward-looking information about the research and development program of NexBio and the potential efficacy of product candidates that might result from programs that involve substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development activities; decisions by regulatory authorities regarding whether and when to permit the clinical investigation of or approve any drug applications that may result from the programs as well as their decisions regarding labeling and other matters that could affect the commercial potential of product candidates that may result from the program; and competitive developments.


'/>"/>
SOURCE NexBio
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Biology in Pico-Liter Droplets is Focus of Presentation at LabAutomation 2009
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
4. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
5. Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
6. Endo Pharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
7. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
8. Martek to Present at 11th Annual ICR XChange
9. Ikaria(R) to Present at 27th Annual JPMorgan Healthcare Conference
10. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
11. ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the “hairy ... a depiction of a system of linkages and connections so complex and dense ... of computer science at Worcester Polytechnic Institute (WPI) and director of the university’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Market with the addition of its newest module, US Hemostats & Sealants. , ... thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in ...
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
Breaking Biology Technology:
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):